Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.44
-0.0800-5.26%
Post-market: 1.500.0599+4.16%19:59 EDT
Volume:944.36K
Turnover:1.39M
Market Cap:129.52M
PE:-0.56
High:1.55
Open:1.52
Low:1.43
Close:1.52
Loading ...

Evercore ISI Sticks to Their Hold Rating for Cabaletta Bio (CABA)

TIPRANKS
·
25 Jul

Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment

TIPRANKS
·
22 Jul

Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment

TIPRANKS
·
19 Jul

Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment

TIPRANKS
·
17 Jul

Cantor Fitzgerald Keeps Their Buy Rating on Cabaletta Bio (CABA)

TIPRANKS
·
16 Jun

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Jun

Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating

TIPRANKS
·
12 Jun

Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio

TIPRANKS
·
12 Jun

Cabaletta Bio Inc. Announces Public Offering of Common Stock and Warrants to Raise Capital

Reuters
·
11 Jun

Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress

Reuters
·
11 Jun

Cabaletta Bio Stockholders Approve Key Proposals

TIPRANKS
·
10 Jun

Cabaletta Bio Inc. Held Annual Stockholders Meeting

Reuters
·
10 Jun

Cabaletta Bio Reprices Stock Options to Motivate Staff

TIPRANKS
·
20 May

Cabaletta Bio Inc. Announces Repricing of Stock Options to Retain and Motivate Employees

Reuters
·
20 May

Cabaletta Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
17 May

UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating

MT Newswires Live
·
16 May

Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating

TIPRANKS
·
16 May

Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission

MT Newswires Live
·
16 May

Cabaletta Bio price target lowered to $13 from $17 at Citi

TIPRANKS
·
16 May

Cabaletta Bio Is Maintained at Buy by Guggenheim

Dow Jones
·
16 May